Key Segments
By Drug Class
-
Monoclonal Antibodies
-
Oral Disease-Modifying Therapies
-
Injectable Disease-Modifying Therapies
-
Corticosteroids
-
Others
By Disease Type
-
Relapsing-Remitting Multiple Sclerosis (RRMS)
-
Secondary Progressive Multiple Sclerosis (SPMS)
-
Primary Progressive Multiple Sclerosis (PPMS)
-
Clinically Isolated Syndrome (CIS)
By Route of Administration
-
Oral
-
Intravenous Infusion
-
Subcutaneous Injection
-
Intramuscular Injection
By End User
-
Hospitals
-
Specialty Neurology Clinics
-
Retail & Specialty Pharmacies
-
Homecare
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Monoclonal antibodies dominated the market with a 39.00% share in 2025.
The Others Drug Class segment is expected to witness the fastest growth with a CAGR of 11.96% during 2026–2035.
Relapsing-Remitting Multiple Sclerosis (RRMS) dominated the disease type segment with a 67.00% share in 2025.
North America dominated the global market in 2025.